RE: Feelin' Blue9 Apr 2025 21:25
Don’t be patronising Stephen, I know exactly how warrants work..... and also how warrants become not worth the paper they are printed on if a new issue is required at discount.
You assume far too much:-
1. The full year results to 31/12 will likely include costs that were paid after 31/12 - let’s see what the loss comes in at but my money is on it being greater than £2.3m loss - IMO they have no handle whatsoever on cash burn, no desire to really reduce it, paying a BDM an inflated salary who has not brought in any business a really good example but there are others. As a result they will need a further raise quicker. But it’s expected that the placing will come because it always does.
2, The lab is a total albatross around the neck, it eats cash, it has zero paid for contracts and I don’t blame the scientists for that, its BOD direction, no investment in sales and marketing, they think going on a jolly to the USA with mates and getting a round of golf in is the way to get business, it’s not it requires graft and nobody is doing that, working from home with multiple jobs illustrates to me lack of commitment, sorry.
3. To leave 201 with THX for so long shows real poor management and dire business acumen skills, very very poor management but moreover a lack of concern for continued burn of investors cash to fund that poor decision. It’s been closed off but very late in the day.
4. 401 I have said will likely result in an extension, it can’t result in a cash payment because put simply they don’t have any and 8 don’t agree with your analysis that someone else will. It’s a 15 yr old outdated spin out from 201, it costs millions t9 take drugs to trials and this isn’t innovative enough imo compared to others on the market.
5. CLX I think is their only asset with potential but my best estimate is 18-24 moths minimum if not far longer but certainly two or three more raises away. They will be out of cash years before CLX can bring any cash in, its needs more funding, it needs peer reviews and phase1 trials for it once positioned and that’s if it’s good enough.
6. I don’t like the fact that they now have added more BOD members unrelated to women’s health and Cancer, it’s a change of direction and I suspect it’s because they know the concept still unproven in 15 years doesn’t work and now grasping at other verticals. This is a new vertical that will take years to develop, again much longer than the current cash runway can support. That’s wha5 I think, I would order they spend the cash trying to make the existing business viable.
7. To date the biobank has proven to be a total waste of investors cash, the previous owners couldn’t make it viable and business revenue generated to date (none) proves same. IMO technology, AI has advanced so much I actually don’t think their is demand now for it, dated concept. I also know for a fact other biolabs have little demand also so I don’t see how they c